tbuckley/cabot-search huggingface dataset:
Abstract 14879: Comparing the Risk of Heart Failure Among Different Dipeptidyl Peptidase 4 Inhibitors
Authors: Jou Wei Lin, Chia-Hsuin Chang, Mei-Shu Lai
Journal: Circulation (2015)

Introduction: Dipeptidyl peptidase 4 (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes mellitus by increasing incretin levels, inhibiting glucagon release, and augmenting insulin secretion. Previous trials raised safety concerns regarding a potential risk of hospitalization for heart failure (HF), but the most recent TECOS trial suggests that adding sitagliptin to usual care did not increase the risk. The objective of this study was to compare the risk of hospitalization for HF among different types of DDP-4 inhibitors. Methods: Diabetic patients who started to use sitagliptin, saxagliptin, and vildagliptin between 2011 and 2013 were identified from Taiwan's National Health Insurance (NHI) claims database. The outcome of interest was the first hospitalization due to HF (ICD-9-CM cod 428). The patients were followed from drug initiation to the outcome occurrence, death or disenrollment from NHI, one year after treatment initiation, or study termination (December 31, 2013). A Cox proportional hazards regression model adjusted for baseline characteristics was used to calculate the hazard ratios (HR) and their 95% confidence intervals, using sitagliptin as the reference group. Results: A total of 239,669 patients, including 159,330 sitagliptin, 38,561 saxagliptin, and 41,778 vildagliptin initiators, were included in the analysis. The mean age of 62.2 years and 52% were male. With a follow-up period ranging from 269 days (vildagliptin) to 313 days (sitagliptin), the crude incidence rate of HF was 2.77, 2.63, and 1.91 per 100 person-years for sitagliptin, saxagliptin, and vildagliptin, respectively. Saxagliptin had a similar HF risk (HR: 0.98, 95% CI: 0.91-1.06) compared to sitagliptin while vildagliptin was associated with a lower risk of HF (HR: 0.85, 95% CI: 0.78-0.93). Conclusions: The safety profile was not all the same among different types of DPP-4 inhibitors in diabetic patients. Vildagliptin was associated with a lower risk of HF than sitagliptin and saxagliptin.
Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza)
Authors: V. Conteduca, O. Caffo, L. Galli, A. Maugeri, E. Scarpi, F. Maines, V. Chiuri, C. Lolli, S. Kinspergher, G. Schepisi, M. Santoni, D. Santini, L. Fratino, S.L. Burgio, S. Salvi, C. Menna, U. De Giorgi
Journal: Annals of Oncology (2017)
Adult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists
Authors: N. Penel, J.-M. Coindre, A. Giraud, P. Terrier, D. Ranchere-Vince, F. Collin, S. Le Guellec, C. Bazille, M. Lae, G. De Pinieux, I. Ray-Coquard, S. Bonvalot, A. Le Cesne, Y.-M. Robin, E. Stoeckle, F. Ducimetiere, M. Toulmonde, J.-Y. Blay
Journal: Annals of Oncology (2017)
Dos brotes de parotiditis en niños vacunados con cepa Rubini en España, indicando una baja eficacia de la vacuna
Authors: C Pons, T Pelayo, I Pachon, A Galmes, L González, C Sánchez, F Martinez
Journal: Eurosurveillance (2000)

El articulo comprende un estudio descriptivo de dos brotes de parotiditis en Espana en 1998 y un estudio de eficacia de la vacuna utilizada. Los resultados sugieren una menor efectividad de la vacuna que utiliza la cepa Rubini, en el caso del componente de la parotiditis.
Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
Authors: C. Yoo, B. Han, K-P. Kim, H.S. Kim, J.H. Kim, H-M. Chang, B-Y. Ryoo, D.Y. Zang
Journal: Annals of Oncology (2017)
Rotavirus na Irlanda
Authors: B Cryan, M Lynch, D Whyte
Journal: Eurosurveillance (1997)

A diarreia aguda e a mais frequente causa singular de morbilidade e mortalidade em todo o mundo. Estima-se em pelo menos 5 milhoes o numero de mortes que ocorrem em cada ano por diarreia infecciosa, nos paises em via de desenvolvimento (1). As criancas muito jovens sao particularmente susceptiveis a infeccao e a mortalidade neste grupo e a mais elevada. O Rotavirus e o agente enteropatogenico mais frequente nas criancas, tanto nos paises em vias de desenvolvimento, como nos paises desenvolvidos. Uma caracteristica notavel das infeccoes a rotavirus nos climas temperados, e a sua sazonalidade. Em contraste com outros agentes enteropatogenicos, que sao mais frequentes durante os meses quentes do ano, a “epoca” do rotavirus situa-se no inverno e primavera. Tipicamente sao as criancas com menos de 2 anos de idade as mais afectadas e o rotavirus pode ser responsavel por admissoes nos servicos de pediatria que chegam a 50%, durante os meses de inverno (2).
Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study
Authors: S. Beslija, T. Ceric, B. Hasanbegovic, A. Kurtovic-Kozaric, A. Pasic, N. Mahic, M. Kalamujic, A. Cardzic, J. Alidzanovic, I. Marjanovic, A. Mekic-Abazovic
Journal: Annals of Oncology (2017)
Sharing resources online is central to medical research and teaching
Authors: Angelica Sharma, Samuel Chun
Journal: BMJ (2017)

Mohammadi discusses the American Diabetes Association’s attempt to censor what delegates at its meeting tweeted.1

Conferences can be extortionately expensive to attend in person. I (AS) received funding from my medical school to attend the Diabetes UK 2017 conference, which did not lack a social media presence—wi-fi passwords were widely distributed to encourage sharing views online. …
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Authors: Matthew P. Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso, Orit C. Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C. Smith, Nawel Bourayou, Angelo Di Leo
Journal: Journal of Clinical Oncology (2017)

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Perfectly matched 20-nucleotide guide RNA sequences enable robust genome editing using high-fidelity SpCas9 nucleases
Authors: Dingbo Zhang, Huawei Zhang, Tingdong Li, Kunling Chen, Jin-Long Qiu, Caixia Gao
Journal: Genome biology (2017)

High-fidelity SpCas9 variants (eSpCas9 and SpCas9-HF1) have been engineered to reduce off-target effects. We found that changes in guide RNA length induced significant reductions in the editing activities of SpCas9 variants in plant cells. Single guide RNAs harboring precise, perfectly matched 20-nucleotide guide sequences are necessary for high on-target editing activities of eSpCas9 and SpCas9-HF1. Precise 20-nucleotide guide sequences derived from tRNA–sgRNA precursors enable robust on-target editing by these variants with enhanced specificity. Our work reveals an effective way of enhancing the use of the high-fidelity SpCas9 nucleases for efficient and precise genome engineering.
Two thirds of Europe’s psychiatric trainees are looking to migrate
Authors: Matthew Limb
Journal: BMJ (2017)

Researchers have identified a large “willingness to migrate” among psychiatric trainees in Europe, that could leave some countries at high risk of “brain drain.”1

Albania, Bulgaria, Cyprus, Romania, and Ukraine were among the countries most likely to lose trainees and face shortages because they might not be replaced, according to a study of 2013-14 survey data recently published.

In the survey of 2281 psychiatry trainees in 33 countries, two thirds were eager to migrate elsewhere at some point in their careers and half were considering leaving “now.” The authors said that this is the largest ever study of psychiatric trainees in Europe.

More than a quarter of trainees had already taken practical …
Anti-PD1 therapy with nivolumab in sarcoma.
Authors: Luca Paoluzzi, Munir V. Ghesani, Adrienne Cacavio, Amy Rapkiewicz, Gerald Rosen
Journal: Journal of Clinical Oncology (2016)

11047 Background: Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and bone sarcomas have been shown to express PD-1 ligand. Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies, has recently emerged as an effective anticancer strategy in multiple malignancies. Methods: We retrospectively analyzed a cohort of patients (pts) with relapsed metastatic sarcomas, who were treated with nivolumab provided under a patient assistance program from the manufacturer. Pts underwent CT or PET/CT imaging at baseline and after at least 6 doses of nivolumab; RECIST criteria were used for response assessment. Results: Twenty-three pretreated pts with metastatic soft tissue (STS, N = 20) or bone sarcoma (N = 3), received IV nivolumab 3mg/kg every 2 weeks from July 2015 to January 2016. Median age was 58 (24-78), male:female was 10:13; ECOG PS was 0-1 in 19 pts, 2 in 4 pts; the median number of previous treatments was two (0-5); the median number of nivolumab cycles was six; thirteen pts concomitantly received the tyrosine kinase inhibitor pazopanib at 800mg daily. The most common side effect was grade 1 or 2 LFT elevations (9 pts, 5 of them receiving pazopanib); grade 3-4 toxicity occurred in 4 pts: grade 4 pneumonitis in 1, grade 3 colitis in 1 and grade 4 LFT elevations in 2 pts. Fourteen pts receiving at least 6 cycles thus far were evaluable for response. We observed three partial responses: one dedifferentiated chondrosarcoma, one intimal sarcoma, (neither receiving pazopanib) and one proximal epithelioid sarcoma (on pazopanib); a mixed response/progression in a leiomyosarcoma (LMS); a mixed partial response/stability of disease in a dedifferentiated liposarcoma; 5 stable disease: 1 mesenchymal chondrosarcoma, one alveolar soft part, 3 LMS; 4 progression of disease (PD): 3 LMS, one synovial sarcoma. Clinical benefit (response + stability) was observed in 9 pts. Three pts died: 1 of PD, 1of an accidental fall and 1 of surgical complications. Conclusions: Collectively, our data provide a rationale for further exploring the efficacy of nivolumab and other checkpoint inhibitors in soft tissue and osteosarcoma.
Abstract 15376: Serum Neutrophil Gelatinase-Associated Lipocalcin is Independently Associated With Mortality in Acute Coronary Syndromes
Authors: Staale H Nymo, Marianne Hartford, Thor Ueland, Arne Yndestad, Thomas Karlsson, Pål Aukrust, Kenneth Caidahl
Journal: Circulation (2013)

Aim:  Neutrophil Gelatinase-Associated Lipocalcin (NGAL) is increased in the circulation of patients with cardiovascular (CV) disease, and has been linked to kidney function as well as matrix degradation and inflammation. We hypothesized that circulating NGAL could give prognostic information for patients with acute coronary syndrome (ACS) in addition to Global Registry of Acute Coronary Events (GRACE) score and other established markers.   Methode:  We assessed the associations between circulating NGAL, obtained within 24 hours of admission, and mortality, CV mortality, heart failure (HF), reinfarction, stroke and the combined endpoint CV mortality, HF or reinfarction in 1121 patients admitted with ACS.   Results:  After adjustment for GRACE score, left ventricular ejection fraction (LVEF), Pro brain natriuretic peptide (BNP), and C-reactive protein (CRP), NGAL was associated with mortality (hazard ratio [HR] 1.41, p=0.02 ) and the combined endpoint (HR 1.45, p=0.006) during long-term follow-up (median 91 months). NGAL was also significantly associated with the short-term (3 months) and late long term (median 129 months) mortality after adjustment (short term HR 2.76, p=0.005, late long term HR 1.51, p   Conclusion:  NGAL is associated with both short and long term prognosis of patients with ACS independently of GRACE score, BNP, CRP and LVEF. NGAL could therefore potentially improve selection of patients needing closer follow up after admission to hospital for ACS.
Loneliness and cognitive dysfunction in elderly cancer patients
Authors: A. Alkan, H. Selvi Öztorun, E. Karcı, G. Tuncay, A. Yaşar, E. Çınar, Y. Ürün, S. Aras, M. Varlı, F. Çay Şenler
Journal: Annals of Oncology (2017)
Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA
Authors: S.B. Goldberg, A. Narayan, A.J. Kole, R.H. Decker, J. Teysir, N.J. Carriero, A. Lee, R. Nemati, S.K. Nath, S.M. Mane, Y. Deng, N. Sukumar, D. Zelterman, D.J. Boffa, K. Politi, S.N. Gettinger, L.D. Wilson, R.S. Herbst, A.A. Patel
Journal: Annals of Oncology (2017)
Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
Authors: E. Samalin, H. Senellart, S. Thezenas, S. Jacquot, S. Ellis, F. Khemissa, M. Ramdani, F. Portales, E. Assenat, T. Mazard, L. Mineur, M. Ychou
Journal: Annals of Oncology (2017)
Mammary analogue secretory carcinoma (MASC): clinical characteristics in 28 ETV6-NTRK3 fusion gene confirmed patients
Authors: E. Boon, M.H. Valstar, W.T.A. van der Graaf, E. Bloemena, S.M. Willems, C.A. Meeuwis, L.A. Smit, M.A.W. Merkx, R.P. Takes, U.E. Flucke, C.M.L. Herpen
Journal: Annals of Oncology (2017)
Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma
Authors: C. Ambrogio, J. Kohler, Z. Zhou, H. Wang, R. Paranal, M. Capelletti, C. Caffarra, S. Li, Q. Lv, D. Santamaria, K.D. Westover, P.A. Jänne
Journal: Annals of Oncology (2017)
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
Authors: H. Gogas, R. Dummer, P.A. Ascierto, A. Arance, M. Mandala, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsová, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, J.W.B. de Groot, N. Yamazaki, C. Loquai, L.A. de Parseval, M. Pickard, V. Sandor, C. Robert, K.T. Flaherty
Journal: Annals of Oncology (2017)
Adjuvant therapy with autologous dendritic cell (DC) vaccine based on cancer-testis antigens (CaTeVac) in melanoma patients
Authors: A. Novik, I. Baldueva, S. Protsenko, T. Nehaeva, A. Danolova, N. Pipia, N. Olisova, M. Kornienko, T. Danilova
Journal: Annals of Oncology (2017)
CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
Authors: M. De Laurentiis, M. Martin Jimenez, A. Ring, P. Cottu, K. Zhou, J. Wu, J.P. Zarate, C. Zamagni
Journal: Annals of Oncology (2017)
Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis
Authors: I. Carandina, L. Belluomini, F. Bonetti, B. Urbini, F. Daniel, F. Lancia, L.R. Martella, I. Toma, A. Moretti, E. Bannò, C. Nisi, L. Da Ros, A. Frassoldati
Journal: Annals of Oncology (2017)
Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort
Authors: Viktoriya L. Kim, Ngaire A. Coombs, Karl J. Staples, Kristoffer K. Ostridge, Nicholas P. Williams, Stephen A. Wootton, Jeanne-Marie Devaster, Emmanuel Aris, Stuart C. Clarke, Andrew C. Tuck, Simon C. Bourne, Tom M.A. Wilkinson
Journal: European Respiratory Journal (2017)

Eosinophilic inflammation in chronic obstructive pulmonary disease (COPD) predicts response to treatment, especially corticosteroids. We studied the nature of eosinophilic inflammation in COPD prospectively to examine the stability of this phenotype and its dynamics across exacerbations, and its associations with clinical phenotype, exacerbations and infection.127 patients aged 40-85 years with moderate to very severe COPD underwent repeated blood and sputum sampling at stable visits and within 72 h of exacerbation for 1 year.Blood eosinophils ≥2% was prevalent at baseline, and predicted both predominantly raised stable-state eosinophils across the year (area under the curve 0.841, 95% CI 0.755-0.928) and increased risk of eosinophilic inflammation at exacerbation (OR 9.16; p<0.001). Eosinophils ≥2% at exacerbation and eosinophil predominance at stable visits were associated with a lower risk of bacterial presence at exacerbation (OR 0.49; p=0.049 and OR 0.25; p=0.065, respectively). Bacterial infection at exacerbation was highly seasonal (winter versus summer OR 4.74; p=0.011) in predominantly eosinophilic patients.Eosinophilic inflammation is a common and stable phenotype in COPD. Blood eosinophil counts in the stable state can predict the nature of inflammation at future exacerbations, which when combined with an understanding of seasonal variation provides the basis for the development of new treatment paradigms for this important condition.
Improving quality of life relies on valid outcome measures as well as drugs
Authors: Rupert C Jones, Matthew Masoli, Joseph W Lanario, Michael E Hyland
Journal: BMJ (2017)

The review from the Drug and Therapeutics Bulletin on managing difficult to treat asthma1 states that studies of novel biological agents have shown marked improvements in the frequency of exacerbations and healthcare consumption and reductions in oral steroid dosage but that limited evidence shows benefits in quality of life. Failure to detect quality of life …
Molecular subtyping of tumors from patients with familial glioma
Authors: Vanessa Y Ruiz, Corinne E Praska, Georgina Armstrong, Thomas M Kollmeyer, Seiji Yamada, Paul A Decker, Matthew L Kosel, Jeanette E Eckel-Passow, Daniel H Lachance, Matthew N Bainbridge, Beatrice S Melin, Melissa L Bondy, Robert B Jenkins
Journal: Neuro-Oncology (2017)

Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype.
Polymeric nanoparticles developed by vitamin E-modified aliphatic polycarbonate polymer to promote oral absorption of oleanolic acid
Authors: Wenjuan Zhang, Chufan Liang, Hao Liu, Zhenbao Li, Rui Chen, Mei Zhou, Dan Li, Qing Ye, Cong Luo, Jin Sun
Journal: Asian Journal of Pharmaceutical Sciences (2017)

Oleanolic acid (OA) exhibited good pharmacological activities in the clinical treatment of hypoglycemia, immune regulation, acute jaundice and chronic toxic hepatitis. However, the oral delivery of OA is greatly limited by its inferior water solubility and poor intestinal mucosa permeability. Herein, we developed a novel polymeric nanoparticle (NP) delivery system based on vitamin E modified aliphatic polycarbonate (mPEG-PCC-VE) to facilitate oral absorption of OA. OA encapsulated mPEG-PCC-VE NPs (OA/mPEG-PCC-VE NPs) showed uniform particle size of about 170 nm with high drug loading capability (8.9%). Furthermore, the polymeric mPEG-PCC-VE NPs, with good colloidal stability and pH-sensitive drug release characteristics, significantly enhanced the in vitro dissolution of OA in the alkaline medium. The in situ single pass intestinal perfusion (SPIP) studies performed on rats demonstrated that the OA/mPEG-PCC-VE NPs showed significantly improved permeability in the whole intestinal tract when compared to OA solution, especially for duodenum and colon. As a result, the in vivo pharmacokinetics study indicated that the bioavailability of OA/mPEG-PCC-VE NPs showed 1.5-fold higher than commercially available OA tablets. These results suggest that mPEG-PCC-VE NPs are a promising platform to facilitate the oral delivery of OA.
Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO)
Authors: Francesco Acerbi, Morgan Broggi, Karl-Michael Schebesch, Julius Höhne, Claudio Cavallo, Camilla De Laurentis, Marica Eoli, Elena Anghileri, Maura Servida, Carlo Boffano, Bianca Pollo, Marco Schiariti, Sergio Visintini, Cristina Montomoli, Lorenzo Bosio, Emanuele La Corte, Giovanni Broggi, Alexander Brawanski, Paolo Ferroli
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Sodium fluorescein is a dye that, intravenously injected, selectively accumulates in high-grade glioma (HGG) tissue through a damaged blood–brain barrier. In this article, the final results of a multicentric prospective phase II trial (FLUOGLIO) on fluorescein-guided HGG resection through a dedicated filter on the surgical microscope were reported. Methods: Patients with suspected HGGs considered suitable for removal were eligible to participate in this trial. Fluorescein was intravenously injected at a dose of 5 to 10 mg/kg. The primary endpoint was the percentage of patients with histologically confirmed HGGs, without contrast-enhancing tumor at the immediate postoperative MRI. Secondary endpoints were PFS, residual tumor on postoperative MRI, overall survival, neurologic deficits, and fluorescein-related toxicity. The sensitivity and specificity of fluorescein in identifying tumor tissue were estimated by fluorescent and nonfluorescent biopsies at the tumor margin. The study was registered on the European Regulatory Authorities website (EudraCT 2011-002527-18). Results: Fifty-seven patients aged 45 to 75 years were screened for participation, and 46 were considered for primary and secondary endpoints. Mean preoperative tumor volume was 28.75 cm3 (range, 1.3–87.8 cm3). Thirty-eight patients (82.6%) underwent a complete tumor removal. Median follow-up was 11 months. PFS-6 and PFS-12 were 56.6% and 15.2%. Median survival was 12 months. No adverse reaction related to SF administration was recorded. The sensitivity and specificity of fluorescein in identifying tumor tissue were respectively 80.8% and 79.1%. Conclusions: Fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and enables a high percentage of contrast-enhancing tumor in patients with HGGs. Clin Cancer Res; 24(1); 52–61. ©2017 AACR.